

Kelderman Kim  
 Form 4  
 May 02, 2019

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**Kelderman Kim**

2. Issuer Name and Ticker or Trading Symbol  
**BIO-TECHNE Corp [TECH]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
**614 MCKINLEY PLACE NE**

3. Date of Earliest Transaction (Month/Day/Year)  
**05/01/2019**

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 \_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)  
**President, Diagnostics & Genom**

(Street)  
**MINNEAPOLIS, MN 55413**

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  |                                | (A) or (D) Code V Amount (D) Price                                |   |  |   |
| Common Stock                    | 05/01/2019                           |  | M                              | 1,667 A \$ 202.13   | 1,667   | D  |   |
| Common Stock                    | 05/01/2019                           |  | F                              | 844 D \$ 202.13   | 823   | D  |   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

Edgar Filing: Kelderman Kim - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | Amount or Number of Shares |                            |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|----------------------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                      | Amount or Number of Shares |
| Restricted Stock                           | \$ 0   | 05/01/2019                           |  | M                              | 1,667   | 05/01/2019   | 05/01/2025  | Common Stock               | 1,667                      |
| Restricted Stock Units                     | <u>(1)</u>   |                                      |  |                                |   | <u>(2)</u>   | 05/01/2025  | Common Stock               | 3,333                      |
| Restricted Stock Units                     | <u>(1)</u>   |                                      |  |                                |   | <u>(3)</u>   | <u>(3)</u>  | Common Stock               | 1,691                      |
| Stock Options (Right to buy)               | \$ 177.32  |                                      |  |                                |   | <u>(4)</u>   | 08/08/2025  | Common Stock               | 12,044                     |
| Stock Options (Right to buy)               | \$ 177.32  |                                      |  |                                |   | <u>(3)</u>   | 08/08/2025  | Common Stock               | 9,033                      |
| Stock Options (Right to buy)               | \$ 150.78  |                                      |  |                                |   | <u>(5)</u>   | 05/01/2025  | Common Stock               | 2,652                      |
| Stock Options (Right to buy)               | \$ 150.78  |                                      |  |                                |   | <u>(6)</u>   | 05/01/2025  | Common Stock               | 7,348                      |

## Reporting Owners

| Reporting Owner Name / Address         | Relationships |           |                             |       |
|--|---------------|-----------|-----------------------------|-------|
|  | Director      | 10% Owner | Officer                     | Other |
| Kelderman Kim<br>614 MCKINLEY PLACE NE |               |           | President,<br>Diagnostics & |       |

MINNEAPOLIS, MN 55413

Genom

## Signatures

/s/ Brenda S. Furlow, attorney in fact for Kelderman, Kim pursuant to Power of Attorney  
previously filed

05/02/2019

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (2) Vests 1,666 shares each on 5/1/2020 and 1,667 shares on 5/1/2021
- (3) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (4) 3,011 shares vest on each of 8/8/2019, 8/8/2020, 8/8/2021 and 8/8/2022
- (5) 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022
- (6) 1,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.